Tag: IN.PACT

Episode 4: Real world data show IN.PACT Admiral DCB is “very...

 In this penultimate episode of a special five-part series on the history of drug-coated balloons (DCBs), Jos van den Berg (Lugano, Switzerland) is joined...

VIVA 2021: IN.PACT Admiral DCB found to provide “high five-year freedom...

Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically-driven target lesion revascularisation (TLR) among prespecified chronic total occlusion (CTO),...

Episode 3: The unique recipe for long-term clinical benefit with IN.PACT™...

In this third episode of a special five-part series on the history of DCBs, Jos van den Berg (Lugano, Switzerland) moderates a Vascular News roundtable discussion...
trerotola misra tan av access dcbs drug coated balloons

More mixed results for DCBs in AV access maintenance as evidence...

Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...

Episode 2: Are all peripheral drug-coated balloons created equal?

 “Not all Drug-Coated Balloons (DCBs) are created equal”, Juan Granada (New York, USA), tells Vascular News in this second episode of a five-part series on the history of DCBs. Granada discusses why there...

Trialists’ insights on the 2-year results from the COMPARE trial

NOTE: This video is ONLY available to watch in selected countries and geographies  Sabine Steiner (Leipzig, Germany) sits down with Michael Jaff, the CMO...

‘Indisputable evidence’ that DCB is the “gold standard” for treating vascular...

NOTE: This video is ONLY available to watch in selected countries and geographies Tobias Steinke (Düsseldorf, Germany), Matteo Tozzi (Varese, Italy) and Robert Shahverdyan...

Lower-dose SurVeil DCB achieves non-inferiority with IN.PACT Admiral balloon

 Kenneth Rosenfield (Boston, USA) speaks to Vascular News about the TRANSCEND trial, a non-inferiority randomised controlled trial, which looked to demonstrate safety and efficacy of the...

IN.PACT Global study shows DCB “safe and effective” in clinically-complex CLI...

Michel Reijnen (Arnhem, Netherlands) talks to Vascular News about the four-year IN.PACT Global study results, focusing on the 156 patients in the study who...

IN.PACT™ AV Access trial shows improvement in patency “for the entire...

 A trio of vascular experts including Raphaël Coscas (Paris, France), Alexandros Mallios (Paris, France) and Kate Steiner (Stevenage, UK) discuss the key findings of...

New England Journal Of Medicine publishes “outstanding” six-month IN.PACT AV Access™...

NOTE: This video is ONLY available to watch in selected countries and geographies Robert Lookstein (New York, USA; principal investigator) and Andrew Holden (Auckland,...

“Starting to close the door on the paclitaxel controversy”: Late-breaking trials...

Findings from a series of late-breaking trials in the endovascular field were presented recently at TCT Connect (14–18 October, virtual), the 32nd annual scientific...

Impressions from LINC 2020: Strong clinical and economic case for widespread...

NOTE: This video is ONLY available to watch in selected countries and geographies Andrew Holden (Auckland, New Zealand), Alexandros Mallios (Paris, France), Robert Lookstein (New...

COMPARE RCT shows similar key outcomes between low- and high-dose drug-coated...

The first head-to-head randomised controlled trial to directly compare two different drug-coated balloons—the lower-dose density (2μg/mm2) Ranger and higher-dose density (3.5μg/mm2) IN.PACT—showed similar results...

LINC 2020: High- and low-dose paclitaxel-coated balloons exhibit comparable results at...

At the 2020 Leipzig Interventional Course (28–31 January, Leipzig, Germany), Sabine Steiner (University of Leipzig, Leipzig, Germany) presented one-year results of the COMPARE-RTC of...

A panel of experts comments on IN.PACT AV ACCESS data

NOTE: This video is ONLY available to watch in selected countries and geographies   Jos van den Berg (Lugano, Switzerland) speaks to Andrew Holden (Auckland, New...

Webinar: Safety of paclitaxel devices—What does the evidence say?

Jos van den Berg (Lugano, Switzerland), Antonio Micari (Bergamo, Italy) and Marianne Brodmann (Graz, Austria) sit down after a specially convened US FDA panel...

Patient-level analysis shows no correlation between paclitaxel and mortality—reactions from LINC

 Renowned experts expressed confidence in the continued use of paclitaxel-coated devices after independent patient-level data presented at LINC 2019 did not show correlation between...
Japanese

Three-year Japanese results show IN.PACT Admiral DCB offers “consistent and durable”...

The IN.PACT Admiral drug-coated balloon (DCB; Medtronic) exhibits a consistent and durable treatment effect in “a more complex patient demographic than typically seen in...

IN.PACT Admiral DCB receives FDA approval for long SFA lesions

Medtronic has announced that it has received US Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon (DCB) to treat long superficial...
Andrew Holden inpact admiral

Andrew Holden: Update on the IN.PACT AV Access trial

Andrew Holden spoke to Vascular News at LINC 2018 (Leipzig Interventional Course; 30 January–2 February, Leipzig, Germany) about the new data from the IN.PACT...

IN.PACT SFA Japan trial shows significantly higher patency compared with PTA...

New two-year results from the IN.PACT SFA Japan trial were presented at the Leipzig Interventional Course (LINC; 30 January–2 February, Leipzig, Germany) by Osamu...

First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...

Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...

LINC 2018 data highlight IN.PACT Admiral as safe and effective treatment...

Medtronic added to its body of clinical evidence supporting the IN.PACT Admiral drug-coated balloon with new presentations that demonstrated durable and consistent clinical outcomes...

First patient enrolled in study of Medtronic IN.PACT arteriovenous access drug-coated...

The first patient has been enrolled in Medtronic’s IN.PACT arteriovenous (AV) access drug-coated balloon (DCB) study for use in patients with end-stage renal disease. The...

Consistent results for Medtronic IN.PACT Admiral in complex peripheral artery disease...

Two new sub-analyses from the IN.PACT Global Study of the IN.PACT Admiral in patients with peripheral artery disease have been reported at the annual...

Medtronic launches European below-the-knee clinical study of drug-coated balloon

Medtronic has launched the IN.PACT BTK study to evaluate the effectiveness of using a drug-coated balloon in patients with below-the-knee (BTK) peripheral artery disease. This...

Results from Asia and Belgium demonstrate consistent results from Medtronic IN.PACT...

New data presented at the 2017 Leipzig Interventional Course (LINC) have demonstrated strong efficacy and consistent outcomes for Medtronic’s IN.PACT Admiral drug-coated balloon across...

REALITY trial enrols first patient in study evaluating Medtronic directional atherectomy...

Medtronic and VIVA Physicians reported on 27 July 2016 the first patient enrolled in the REALITY Study. The VIVA-sponsored study is assessing outcomes for...